Zenas BioPharma (ZBIO)
Develops obexelimab, a licensed antibody that quiets B-cell activity in immune diseases without depleting the cells.
$32.44
Pre-market−0.65 (−1.98%)
At close$33.09(+3.47%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions151 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 94.30% | 61.46M shares | |
| Insiders9 holders · as of Jun 17, 2026 | 4.55% | 2.97M shares | |
| Strategic holders1 holder · as of Oct 15, 2025 | 7.67% | 5.00M shares | |
| Adds to | 106.52% |
65.18M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 106.52%; nothing is left for Other.
Institutions13F, as of Jun 30, 2026
151 holders · 61.46M shares · 33 new positions · 94 increased · 41 reduced · 23 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 9.51M | 14.59% | +424.7K | Aug 13, 2026 |
| Sr One Capital Management, LP | 5.04M | 7.73% | 0 | Aug 12, 2026 |
| Nea Management Company, LLC | 4.02M | 6.17% | 0 | Aug 14, 2026 |
| Enavate Sciences GP, LLC | 3.92M | 6.01% | 0 | Aug 14, 2026 |
| Federated Hermes, Inc. | 3.12M | 4.78% | −10.2K | Aug 12, 2026 |
| BlackRock, Inc. | 2.69M | 4.12% | +648.7K | Aug 7, 2026 |
| Capital International Investors | 2.50M | 3.84% | +68.9K | Aug 12, 2026 |
| Polar Capital Holdings PLC | 2.41M | 3.70% | −135.7K | Aug 14, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 14.30% | 7.65M | 13G | Feb 5, 2026 ↗ |
| InnoCare Pharma Inc. | 9.40% | 5.00M | 13G | Oct 15, 2025 ↗ |
| Enavate Sciences GP, LLCincl. Zebra Aggregator, LP | 9.00% | 3.76M | 13D | Sep 23, 2024 ↗ |
| SR One Capital Management, LLCincl. Simeon George, SR One Capital Opportunities Fund I, LP +5 more | 7.70% | 5.04M | 13D | Aug 17, 2026 ↗ |
| Xencor, Inc. | 7.40% | 3.10M | Oct 21, 2024 ↗ | |
| NEA 18 Venture Growth Equity, L.P.incl. Edward T. Mathers, Scott D. Sandell +8 more | 6.60% | 2.61M | Sep 25, 2024 ↗ | |
| Moulder Leon O Jrincl. Tellus BioVentures, LLC, Leon O. Moulder, Jr. Revocable Trust U/A dtd 9/9/2008 | 5.09% | 3.22M | 13D | May 5, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| May 18, 2026 | Leon O. Jr Moulderdirector, officer: Chief Executive Officer | Purchase | 60,000 | $16.88 | 96,928 |
| Apr 28, 2026 | Leon O. Jr Moulderdirector, officer: Chief Executive Officer | Purchase | 25,000 | $18.02 | 1,751,039 |
| Apr 29, 2026 | Leon O. Jr Moulderdirector, officer: Chief Executive Officer | Purchase | 35,000 | $17.62 | 1,786,039 |
| Mar 31, 2026 | Hongbo Ludirector | Purchase · 2 lots | 78,768 | $19.93 | 426,736 |
| Mar 31, 2026 | Fairmount Funds Management LLCdirector | Purchase | 150,000 | $20.00 | 2,359,025 |
| Mar 30, 2026 | Leon O. Jr Moulderdirector, officer: Chief Executive Officer | Purchase | 20,000 | $18.23 | 1,692,039 |
| Mar 31, 2026 | Leon O. Jr Moulderdirector, officer: Chief Executive Officer | Purchase | 34,000 | $19.31 | 1,726,039 |
| Feb 12, 2026 | Patricia L. Allendirector | Purchase · 3 lots | 15,700 | $24.85 | 15,700 |
| Feb 13, 2026 | Patricia L. Allendirector | Purchase | 4,160 | $26.36 | 19,860 |
| Feb 11, 2026 | Hongbo Ludirector | Purchase | 25,985 | $22.50 | 347,968 |
CongressHouse and Senate disclosures
Not reported.